Background: Accurate and reliable clinical and radiological predictors of intracere-
| Norwegian patient registry
Norwegian patient registry (NRF) is a national administrative health registry containing person identifiable information on all inpatient and outpatient treatment by the public Norwegian specialist health care services. The database contains demographic, administrative, and health related data, such as dates of admission and discharge, and primary and unlimited number of secondary diagnoses according to the 10th revision of the International Classification of Diseases (ICD-10), including codes for diagnostic and therapeutic procedures.
All discharge diagnoses are exclusively assigned by the physicians treating the patient, and cannot later be altered. The registry receives data monthly and is used for reimbursement purposes, hospital activity statistics, and research (Varmdal et al., 2016) . Coding of ICH discharge diagnoses in the NPR is of high quality, with positive predictive values for ICH hospital admissions exceeding 95% (Oie et al., 2018) .
| Study population
The study was carried out within the population of Sør-Trøndelag County between 1 January 2008 and 31 December 2014. The study population of 298,000 individuals (2009 Census, Statistics Norway) is served by St. Olavs University Hospital, the only hospital in this defined geographical region providing inpatient treatment of ICH.
Patients with a primary diagnosis of spontaneous ICH (ICD-10 codes I61.0-I61.9) and a residential address within Sør-Trøndelag County were included in the study. After review of hospital records and diagnostic images, we excluded traumatic ICH, ICH related to intracranial tumors, extra-axial intracranial hemorrhages, and ICH related to parenteral thrombolytic treatment (inpatient ICH). Patients with isolated intraventricular hemorrhage were included. Patients whose records were not found, or episodes of ICH occurring outside the study period were excluded from the analyses. Patients from the study area who were hospitalized elsewhere for ICH and subsequently transferred to St. Olavs University hospital were included.
All included patients were aged 18 years or older.
| Baseline recordings
ICH was defined as clinical symptoms of stroke combined with the presence of parenchymal hemorrhage on a cerebral CT (cCT) scan.
Time of ictus was defined as the time when neurological symptoms appeared. Demographic data, comorbidities, clinical and radiological data, and information about surgical interventions were retrieved from the electronic medical records. The Charlson comorbidity index was used to estimate comorbidity, a scoring system predicting 10-year survival in patients with multiple comorbidities. In addition to vascular comorbidities, it includes dementia and malignancy which are often not included in other scoring systems (Charlson, Pompei, Ales, & MacKenzie, 1987; Sundararajan et al., 2004) .
Use of oral antithrombotic medications (OAM) at the time of hospital admission was also registered, including both antiplatelet agents (aspirin, dipyridamole, acetylsalicylic acid-dypiridamole, and clopidogrel) and anticoagulant agents (warfarin, dabigatran, apixaban, and rivaroxaban).
A baseline cCT scan was available for all included patients, except for patients transferred from hospitals outside Norway. Four of the authors, blinded to patient characteristics, assessed all cCTs.
Hematoma location was classified as lobar (cortical or subcortical white matter), deep (thalamus and basal ganglia), brainstem, or cerebellum. Hematoma volume was calculated manually with the formula A × B × C /2 cm 3 (Kothari et al., 1996) . The presence of intraventricular hemorrhage was registered, and a modified Graeb score (mGS) was calculated for intraventricular hemorrhages (Hinson, Hanley, & Ziai, 2010) . Hematoma expansion was determined if sequential brain imaging was available, and defined as a relative parenchymal volume increase of more than 33% from initial to follow-up imaging within 3 to 72 hr (Kuramatsu et al., 2015) .
If more than one follow-up imaging session was performed, the one closest to the 24-hr time was chosen. Patients with hematoma evacuation before any follow-up imaging were excluded from the hematoma expansion analysis.
| Outcome assessment
All included patients were followed up for a minimum of 12 months.
Level of consciousness, determined by Glasgow Coma Scale (GCS), is routinely scored for all patients admitted to the hospital, and was found in the electronic medical records. Functional outcome was determined using the modified Rankin Scale (mRS) score before the ICH, and at 3 and 12 months after ICH. The mRS score prior to and immediately after the ICH is routinely scored on admission to the stroke unit by stroke physicians, nurses, and physiotherapists. Three months after discharge, stroke patients receive either an outpatient or home visit where mRS is usually scored (Indredavik, Fjaertoft, Ekeberg, Loge, & Morch, 2000) . This information is available in the electronic medical records. The mRS scores at 12 months were scored by two of the authors (LRØ, MAM) based on information from the electronic medical records. Patients with mRS of 5 were classified as having severe disability and mRS 6 as dead. As an additional indicator for clinical outcome, cohabitation before and after the ICH was assessed. The date of death was provided by either the electronic medical record or Norwegian Institute of Public Health.
| S TATI S TI C S
Statistical analyses were performed with SPSS 24.0. Descriptive statistics were computed for baseline characteristics. To compare users and nonusers of OAM, we used independent samples t tests for continuous variables, and chi-square test for categorical variables.
Predictors of severe disability or death (mRS 5 and 6) at 3 months were analyzed using Cox regression analyses. Variables from the univariable analyses with a p-value <0.10 were included in the mul- 
| RE SULTS
In total, 561 patients with spontaneous ICH requiring hospitalization were identified in the NPR within the study period, and based on our inclusion and exclusion criteria, 452 patients were included for further analyses.
| Patient characteristics
Crude annual incidence rate between 2008 and 2014 in Sør-Trøndelag County was 21.5 per 100,000 per year. Patient and hematoma characteristics are presented in Table 1 . The mean age was 74.8 years and 45.6% were females. Past history of arterial hypertension was present in 52.7% (n = 238) and a history of diabetes in 11.7% (n = 53). The mean Charlson comorbidity index score was 1.4 (SD 1.6). At the time of the ICH, a total of 56.6% (n = 256) used OAM, with antiplatelet drugs (37.2%) being more frequently used than anticoagulants (22.8%). 14 patients (5.5%) used both antiplatelets and anticoagulants at the time of ICH. Novel oral anticoagulants (NOAC) were introduced in the last part of the inclusion period, and only 1 patient used NOAC (rivaroxaban), whereas the others used warfarin with a mean INR value of 2.8 on admission. As presented in Table 4 , users of OAM were older than nonusers (78.6 vs. 69.4 years, mean difference 9.2 years, 95% CI 7.0-11.3, p < 0.001). In total, 9.5% (n = 43) underwent early surgical treatment for the bleeding. Of these, 6.2% (n = 28) underwent hematoma evacuation, and 0.7% (n = 3) received an additional craniectomy (Table 1) .
| Radiological characteristics
The most common location of the hemorrhage was deep (44.9%, n = 203), followed by lobar (40.9%, n = 185), cerebellar (8.2%, n = 37), brainstem (5.1%, n = 23), and strict intraventricular hemorrhage (0.7%, n = 3) ( Table 1) . Among patients with supratentorial ICH, the prevalence of hypertension was higher in patients with deep location (59.5%) compared to lobar location (50.5%) (p = 0.005).
Overall, the mean baseline hematoma volume was 33.1 ml (SD 45.7).
Intraventricular hemorrhage was observed in 186 patients (41.2%) and hematoma expansion in 46 patients (10.2%). Mean hematoma volume of users of OAM (Table 4 ) was higher than for nonusers (35.8 vs. 26.3 ml, mean difference 9.5 ml, 95% CI 1.2-17.8, p = 0.025).
| Functional outcome
Clinical presentation and functional outcome are presented in Table 2 . Median GCS score on admission was 14 (IQR 6). Median mRS score before the ICH was 1 (IQR 2); for survivors at 3 months, the median mRS was 5 (IQR 3); and at 12 months, median mRS was survivors at 3 months, 52 (18.9%) were severe disabled (mRS 5), and at 12 months, 12 (4.8%) had mRS 5. Functional status before, and at 3 and 12 months is presented in Figure 1 .
The univariate analyses ( CI 0.8-4.2, p < 0.001) remained independent predictors of severe disability or death 3 months after the ICH. In a similar multivariate analysis, only age <75 years was found to be an independent predictor of favorable outcome defined as mRS 0-2 at three months (OR 0.2, 95% CI 0.1-0.3, p < 0.001).
Use of OAM was strongly associated with an increased mortality at 3 months ( Figure 2 ). Among those using OAM, 46.5% (119 of 256 patients) were dead at 3 months, compared to 26.3% (49 of 186) in nonusers (p < 0.001) ( Table 4 ).
Out of the 28 patients that underwent surgical hematoma evacuation, 20 (71.4%) patients had a supratentorial location and 9 (32.1%) an infratentorial location. At 3 months, 2 (4.2%) patients had mRS 3, 10 (52.6%) patients had mRS 4, 7 (36.8%) patients had mRS 5 (severe disability), and 9 (32.1%) patients were dead (mRS 6). We were unable to score mRS for 24 (5.3%) patients at 12 months, as their medical records were missing. However, they were not registered as dead in the Norwegian Institute of Public Health; thus, we know they were alive. Patients who survived the acute hospital stay and were discharged to their homes had significantly smaller hematoma volume than those who were discharged to a nursing home (mean difference 14.4 ml, 95% CI 9.0-19.8, p < 0.001).
TA B L E 2 Clinical presentation

| D ISCUSS I ON
This retrospective population-based study in a high resource setting shows that ICH is associated with high mortality, and the majority of survivors become dependent of care.
Independent predictors of severe disability or death at three months were use of OAM, functional disability prior to the ICH, low GCS score on admission, larger hematoma volume, and presence of intraventricular extension. Only age <75 years was an independent predictor of favorable outcome at three months.
The mortality rate in the present study was 22.1% the first week, 39.2% at 3 months, and 44.9% at 12 months, which is in general agreement with data from previous studies, reporting mortality rates from 25%-50% (Flaherty et al., 2006; Gonzalez-Perez, Gaist, Wallander, McFeat, & Garcia-Rodriguez, 2013; Qureshi et al., 2001; Sacco, Marini, Toni, Olivieri, & Carolei, 2009) . At 3 months, only 15.7%
of the patients had a favorable outcome (mRS <2), correlating well with studies presenting functional independency rates from 12% to 39% (Flemming et al., 2001; Safatli et al., 2016; van Asch et al., 2010) .
However, it is difficult to compare results across studies due to variation in inclusion criteria, outcome measures, and statistical analyses.
In line with previous studies, we found that the patients' initial level of consciousness, baseline hematoma volume, hematoma growth, hydrocephalus, and intraventricular extension were the most important prognostic factors of ICH (Bhatia et al., 2013; Davis et al., 2006; Flemming et al., 2001; Nilsson et al., 2002; Safatli et al., 2016; Sarker et al., 2008) . Given the association of poor outcome with hematoma expansion, accurate and reliable predictors of expansion are needed. In contrast to volume and location, secondary hematoma growth is potentially modifiable, and prevention of such expansion should still be a major therapeutic target in the management of ICH. The spot sign observed on CT angiography (CTA) has been found to independently predict poor outcome (Demchuk et al., 2012) . We did not evaluate the spot sign in our study as TA B L E 3 Factors associated with severe disability or death (mRS score 5-6) at 3-month follow-up | 7 of 9 ØIE Et al.
perihemorrhagic edema has been found to be an independent predictor of functional outcome after ICH (Volbers et al., 2018) .
Incidence of ICH is increasing with age for both genders; however, consistent with previously published studies, neither gender nor age were significant predictors of severe outcome in our study (Broderick et al., 2007; Safatli et al., 2016) . Conflicting results have been reported for hematoma location, and some studies have found infratentorial location to be associated with increased mortality (Safatli et al., 2016) , while others failed to show an association (Bhatia et al., 2013) . In the present study, hematoma location was not an independent prognostic factor of severe disability or death.
The proportion of patients with coexisting medical conditions reflects a generally high prevalence of atherosclerotic vascular disease among patients with spontaneous ICH. More than half of the patients had a history of hypertension, and 1/3 had experienced a cerebrovascular event prior to the ICH in our study. There was no statistically significant association between the 3-month outcome and the presence of comorbidities. Nevertheless, we believe that primary prevention should still remain an important target in the management of ICH.
Overall, we found that more than fifty percent of the ICH were associated with OAM, with antiplatelets being more frequently used than anticoagulants (37.2% vs. 22.8%, respectively). Users of OAM were older and had poorer survival than nonusers. The current use of OAM was an independent predictor of severe disability or death at 3 months. The higher mortality found among patients receiving anticoagulants in our study is consistent with prior studies (Flibotte, Hagan, O'Donnell, Greenberg, & Rosand, 2004; Horstmann et al., 2013) . NOAC-associated ICH is associated with high mortality and unfavorable outcomes (Purrucker et al., 2016) ; however, when compared with warfarin, they were found to be associated with lower risk of in-hospital mortality (Inohara et al., 2018) . NOACs were introduced in the last part of our study, and only one of our included patients used a NOAC. Although aspirin is associated with lower risk of ICH (Garcia-Rodriguez, Gaist, Morton, Cookson, & Gonzalez-Perez, 2013) , previous use of combination antiplatelet therapy in patients with ICH is associated with higher risk of in-hospital mortality (Khan et al., 2017) . Due to differences in study periods, patient populations, and OAM under investigation, it is challenging to compare the effect of OAM on clinical outcomes following ICH across studies. More results from pharmacoepidemiological studies are pending and may provide better real-world estimates for risk of ICH in users of antithrombotic medications (Gulati et al., 2015) .
Patients who survive ICH may have risk factors for future thromboembolic events, but the role of OAM remains a therapeutic dilemma with conflicting evidence and contradictory recommendations (Biffi et al., 2017; Pennlert et al., 2015) . There is currently a lack of solid evidence to guide decisions on whether and when to start or restart treatment in ICH survivors, and both well designed randomized controlled trials and observational studies should be encouraged (Perry et al., 2017) .
In the present cohort, patients who underwent neurosurgical interventions did not exhibit better outcome. At 3 months, more than one third of the patients receiving surgical management were dead (mRS 6), and another one third had severe disability (mRS 5 
